CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
pioglitazonedrug
Likely dose
Pioglitazone 30 mg orally once dailyAI-extracted
Key inclusion· 6
  • ✓Age ≥28 years
  • ✓Confirmed diagnosis of cystic fibrosis
  • ✓FEV1 ≥40% predicted
  • ✓Clinically stable
Key exclusion· 10
  • ✕Investigational agent within 4 weeks prior to screening
  • ✕Chronic daily NSAID or ibuprofen use
  • ✕Chronic daily use of insulin or oral diabetes medications
  • ✕History of hypersensitivity to glitazones

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00322868
NCT00322868N/ACompleted
CompareCT.gov

A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis

University Hospitals Cleveland Medical Center·interventional·Posted May 8, 2006·Updated Feb 23, 2018

In Brief

A clinical study evaluating pioglitazone for Cystic Fibrosis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease. Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens before and after a 4 week treatment period with pioglitazone in clinically stable CF patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
CollaboratorsCystic Fibrosis Foundation

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2006
Enrollment StartApr 1, 2006
Primary CompletionDec 1, 2006
Study CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 20.2 years ago

Interventions

pioglitazonedrug

All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.